Journals / MN Oftalmoloji / 2004 / Cilt: 11 - Sayı: 2

The effect of longterm use of levodopa after sensitive period

Gelişim dönemi sonrası uzun süreli levodopa kullanımının görsel fonksiyonlara etkisi

Pages
157–161
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It is well tolerated without any significant side effects for 2 months.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the tolerability and the effect of longterm levodopa use in anisometropic amblyopes after completion of the sensitive period and failed patching treatment.
📊
Key Findings & Data:Materials and Methods: Twenty-two cases (14 male, 8 female) with a mean age of 11.6±2.7 years were included in the study.
💡
Conclusion & Impact:It is well tolerated without any significant side effects for 2 months.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Görme keskinliği · Levodopa · Göz tembelliği

Abstract

Purpose: To evaluate the tolerability and the effect of longterm levodopa use in anisometropic amblyopes after completion of the sensitive period and failed patching treatment. Materials and Methods: Twenty-two cases (14 male, 8 female) with a mean age of 11.6±2.7 years were included in the study. Levodopa was prescribed according to the weight for 2 months. Visual acuities, binocular functions were measured and patern VEP was recorded before and at 2nd and 6th months after therapy and subjects were seen with 3-4 weeks intervals. Results: The mean Snellen visual acuity in the amblyopic eyes prior to treatment was 0.34 (0.05-0.7) and 0.52 (0.1-0.9) after the treatment (paired t-test, p<0.001) and 0.39 (0.1-0.7) at the end of 6 months (p<0.05). Similarly near visual acuity increased significantly after the treatment (prior to treatment 0.64, after the treatment 0.81 and 0.76 at 6th month) (p<0.001, p<0.05). The mean VEP amplitudes prior to treatment was 8.43±4.77 µV and 9.38±4.81µV after the treatment (Wilcoxon, p<0.05) and 12.86±5.11µV (p>0.05), the difference that was statistically significant initially was not seen at the end of 6th month. The difference in VEP latency was not significant (prior to treatment mean latency was 107.6 msec, after the treatment 106.2 msec and 106.3±4.2 msan at 6th month) (Wilcoxon, p>0.05). Increase in VEP amplitude was significant in sound eyes after treatment (prior to treatment 12.01±5.08 µV, after treatment 13.49±5.17 µV) (paired t-test, p<0.05) however there was no significant change at 6th month (12.86±5.11 V) (p>0.05). Similarly there was no significant change in latency (prior to treatment 104.01 msec, after the treatment 103.77 msec, 6th month 103.9±2.3 msan) (paired t-test, p>0.05). There was no decrease in visual acuity, but 1 line increase in 6 cases and 5 lines increase in 2 cases were achieved. After treatment significant increase in stereopsis was seen (484.5 san arc before the treatment, 216.4 san arc after the treatment, (p<0.001), at 6 months 243.1 san arc (p<0.05). None of the cases ceased treatment due to side effects. Conclusion: Distance and near visual acuity values measured at the end of treatment and 6th month were statistically significantly higher than prior to treatment measurements. Levodopa can increase visual acuity and stereopsis in amblyopia cases who had failed patching treatment. It is well tolerated without any significant side effects for 2 months.

Özet

Amaç: Gelişim dönemi sonrası kapama tedavisi ile başarı sağlanamayan olgularda, uzun süreli levodopa kullanımında ilaç toleransının ve görsel fonksiyonlara etkisinin değerlendirilmesi. Gereç ve Yöntem: Anizometropik ambliyopi tanısı ile izlenen ve kapama tedavisini tamamlamış, yaşları 8 ile 16 arasında (ort: 11.6±2.7 yıl) değişen 22 olguda (14 erkek, 8 kız) çocuğun kilosu gözönüne alınarak, 2 ay süre ile Levodopa verildi. Tedavi başlangıcında uzak ve yakın görme, binoküler fonksiyonlar ölçüldü ve patern VEP kaydedildi. Üç-dört haftalık aralıklarla izlenen olgularda 2. ve 6. ayın sonunda muayene ve patern-VEP tekrarlandı. Bulgular: Tedavi öncesi ambliyop gözde ortalama 0.34 (0.05-0.7) Snellen sırası olan görme keskinliği, tedavi sonrası 0.52 (0.1-0.9), 6 ayın sonunda 0.39 (0.1-0.7) olarak ölçüldü (bağımlı gruplarda t-testi, p 0.05) olarak ölçüldü, başlangıçtaki istatistiksel anlamlı olan artış 6. ayda devam etmemekteydi. Latansdaki azalma anlamlı değildi (ted öncesi 107.6 msan, ted sonrası 106.2 msan, 6. ayda 106.3±4.2 msan) (Wilcoxon, p>0.05). Tam gören sağlam gözlerde de kaydedilen VEP genliği tedavi sonrasında anlamlı artış gösterirken (ted öncesi 12.01±5.08 V, ted sonrası 13.49±5.17 V) (eşleştirilmiş t-testi, p 0.05) fark yoktu. Benzer şekilde latansda da fark yoktu (ted öncesi 104.01 msan, ted sonrası 103.77 msan, 103.9±2.3 msan) (eşleştirilmiş t-testi, p>0.05). Hiçbir olguda görme keskinliğinde azalma olmamış, 6 olguda 1 sıra, 2 olguda ise 5 sıra artış olmuştur. Tedavi sonunda stereopsis değerinde de anlamlı artış elde edildi (önce 484.5 san arc, 2. ay sonunda 216.4 san arc p<0.001, 6. ay sonunda 243.1 san arc, p<0.05). Hiçbir olguda yan etkiye bağlı ilaç tedavisi bırakılmamıştır. Sonuç: Tedavi sonrası ve 6.ayda ölçülen uzak ve yakın görme keskinliği değerleri tedavi öncesine göre istatistiksel olarak anlamlı olarak yüksekti. Vizüel gelişim dönemini tamamlamış ve ambliyopi tedavisi ile başarı sağlanamamış olgularda dopamin tedavisi ile görmede artış ve binoküler fonksiyonlarda düzelme sağlanabilir. İki aylık uzun kullanım döneminde ilaç toleransı iyi olmuştur.

🔖

Cite This Article

ATİLLA, H., ERKAM, N. (2004). The effect of longterm use of levodopa after sensitive period. MN Oftalmoloji, Cilt: 11 - Sayı: 2, 157–161. https://ajindex.com/articles/296127

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Harris JP, Calvert JE, Leendertz JA, Phillipson OT. The influence of dopamine on spatial vision. Eye 1990; 4:806-12
  2. Bear MF, Singer W. Modulation of visual cortical plasticity by acetylcholine and noradrenaline. Nature 1986; 320:172-6
  3. Gottlob I, Stangler-Zuschrott E. Effect of Levodopa on contrast sensitivity and scotomas in human amblyopia. Invest Ophthalmol Vis Sci 1990; 31:776-80
  4. Jensen RJ, Daw NW. Effects of dopamine and its agonists and antagonists on the receptive field properties of ganglion cells in the rabbit retina. Neuroscience 1986; 17:837-55
  5. Leguire LE, Rogers GL, Bremer DL, Walson P, Hadjiconstantinou-Neff M. Levodopa and childhood amblyopia. J Pediatr Ophthalmol Strabismus 1992; 29:290-8
  6. Flynn JT. Levodopa and childhod amblyopia: Discussion. J Pediatr Ophthalmol Strabismus 1992; 29:299
  7. Leguire LE, Rogers GL, Bremer DL, Walson PD, McGregor ML. Levodopa/carbidopa for childhood amblyopia. Invest Ophthalmol Vis Sci 1993; 34:3090-5
  8. Leguire LE, Walson PD, Rogers GL, Bremer DL, McGregor ML. Longitudinal study of levodopa/carbidopa for childhood amblyopia. J Pediatr Ophthalmol Strabismus 1993; 30:354-60
  9. Gottlob I, Charlier J, Reinecke RD. Visual acuities and scotomas after one week levodopa administration in human amblyopia. Invest Ophthalmol Vis Sci 1992; 33:2722-8
  10. Procianoy E, Fuchs FD, Procianoy L, Procianoy F. The effect of increasing doses of levodopa on children with strabismic amblyopia. J AAPOS 1999; 3:337-40
  11. Başmak H, Yıldırım N, Erdinç O, Yurdakul S, Özdemir G. Der effekt der levodopatherapie auf das visuell evozierte potential und die sehscharfe in der Amblyopie. Ophthalmologica 1999; 213:110-3
  12. Öndeş S, Nurlu G, İlhan B, Şener C, Sanaç AŞ. Anizometropik ambliyopide levodopa uygulamasının görsel uyarılmış potansiyeller üzerine etkileri. T Klin Oftalmoloji 1998; 7:92-5
  13. Leguire LE, Rogers GE.Levodopa treatment in childhood amblyopia. Invest Ophthalmol Vis Sci 1991; 32(supplement):820
  14. Gottlob I, Wizov SS, Reinecke RD. Visual acuities and scotomas after 3 weeks’ levodopa administration in adult amblyopia. Graefes Arch Clin Exp Ophthalmol 1995; 233:407-13.